RIBEIRO J.
- Country
- France
- Department
- Medical Oncology
Research Overview
- Evaluation of Preoperative Durvalumab (MEDI4736) in Patients with Early-Stage Untreated Small Triple Negative Breast Cancer
- Phase 3 Randomized Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in HR+/HER2- Metastatic Breast Cancer
- Evaluation of Efficacy and Safety of Abemaciclib, Inavolisib, and Ribociclib in Combination Therapies for Metastatic Breast Cancer Subtypes
Data & Insights
Has run more than one trial at 49 of 252 partner sites.
Specializations
Hematologic Malignancies
The investigator focuses on high‑risk Acute Myeloid Leukemia and related myeloid disorders, including Myelodysplastic Syndromes and chronic myelomonocytic leukemia.
- Relapsed/refractory AML
- High‑risk MDS
- CMML therapeutic strategies
Efforts emphasize novel agents for patients with limited prior treatment options.
MTAP‑Deleted Solid Tumors
Targeted approaches are pursued for cancers harboring methylthioadenosine phosphorylase loss, covering a spectrum of advanced solid malignancies.
- MTAP‑deficient non‑small cell lung cancer
- MTAP‑deleted glioblastoma
- MTAP‑null pancreatic adenocarcinoma
These studies explore metabolic vulnerabilities specific to the MTAP deletion.
HER2‑Targeted Oncology
Clinical work includes HER2‑positive and HER2‑low tumors, spanning breast, gastric and other epithelial cancers.
- HER2‑positive metastatic breast cancer
- HER2‑low breast carcinoma
- HER2‑amplified gastric adenocarcinoma
Therapeutic strategies aim to improve outcomes across HER2‑driven disease subsets.
KRAS G12C Mutated Cancers
Research addresses the KRAS G12C oncogenic driver in multiple tumor types, evaluating emerging targeted inhibitors.
- KRAS G12C non‑small cell lung cancer
- KRAS G12C colorectal carcinoma
- KRAS G12C pancreatic ductal adenocarcinoma
Focus is on precision medicine for patients with this specific mutation.
Cutaneous and Skin‑Associated Malignancies
Investigations include immunotherapy and targeted treatments for malignancies of the skin and its appendages.
- Advanced melanoma
- Merkel cell carcinoma
- Basal cell carcinoma
Efforts target durable responses in high‑risk cutaneous cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.